TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact

Pipeline

Transcenta has established a pipeline of ten innovative molecules in oncology, bone disorders and nephrology. Nine of them are discovered and developed in house.

Oncology pipeline includes multiple innovative and differentiated biologic molecules targeting major cancer pathways which have potential synergistic mechanisms of actions for tumor indications with high unmet medical needs. Our pipeline includes both targeted therapy (TST001) as well as immunotherapy (TST005) that engage either NK cells or T cells to kill tumor cells, or agents that can enhance the anti-tumor activity of the above mentioned therapies by either inhibiting tumor associated fibroblast derived immunosuppressive regulatory protein (TST003) or depleting immunosuppressive Treg cells (TST010) or by enhancing TIL infiltration into the tumor by normalizing vasculature (MSB0254). In addition, these molecules have both broad use on their own but are also highly synergistic with TST001 for gastrointestinal cancers.

Transcenta’s highly differentiated non-oncology pipelines focus on novel indications with high unmet medical needs in bone and kidney diseases. TST002 and TST004 are two differentiated molecules that are designed to treat osteoporosis and complement mediated disease respectively. Both osteoporosis and kidney disease like IgAN are areas of high unmet medical needs and with high market potentials.
Oncology
Drugs
Candidate
Target
Indication
Clinical Trial
Region
Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Rights
Partner
TST001
Claudin 18.2
First-line GC/GEJ
Late-line GC
Late-line PADC
Other Late-line Solid Tumors
Second-line GC
First-line GC/GEJ
2/3 Line GC/GEJ
First-line BTC
Global
China
Global
Global
Global
Global
Global
Global

Drugs Candidate:Claudin 18.2

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
First-line GC/GEJ -Global - Combo with Chemo
Combo with Chemo
Late-line GC -China - Monotherapy
Monotherapy
Late-line PADC -Global - Monotherapy
Monotherapy
Other Late-line Solid Tumors -Global - Monotherapy
Monotherapy
Second-line GC -Global - Combo with Chemo
Combo with Chemo
First-line GC/GEJ -Global - Combo with Nivolumab/Chemo
Combo with Nivolumab/Chemo
2/3 Line GC/GEJ -Global - Combo with Nivolumab
Combo with Nivolumab
First-line BTC -Global - Combo with Chemo
Combo with Chemo
Global
In-house
READ MORE READ MORE
TST005
PD-L1/TGF-β Bi-functional
Solid Tumors (HPV+ and NSCLC, etc.)
Global

Drugs Candidate:PD-L1/TGF-β Bi-functional

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Solid Tumors (HPV+ and NSCLC, etc.) -Global - Monotherapy
Monotherapy
Global
In-house
READ MORE READ MORE
TST003
BMP Antagonist (FIC)
Solid Tumors
Global

Drugs Candidate:BMP Antagonist (FIC)

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Solid Tumors -Global - Monotherapy
Monotherapy
Global
In-house
READ MORE READ MORE
TST006
Claudin 18.2/PD-L1 Bi-specific (FIC)
Solid Tumors
Global

Drugs Candidate:Claudin 18.2/PD-L1 Bi-specific (FIC)

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Solid Tumors -Global - Monotherapy
Monotherapy
Global
In-house
READ MORE READ MORE
TST010
Undisclosed
Solid tumors
Global

Drugs Candidate:Undisclosed

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Solid tumors -Global - Monotherapy
Monotherapy
Global
In-house
READ MORE READ MORE
MSB0254
VEGFR2
Solid Tumors
China

Drugs Candidate:VEGFR2

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Solid Tumors -China - Monotherapy
Monotherapy
Global
In-house
READ MORE READ MORE
MSB2311
PD-L1
TMB-H Solid Tumors
Solid Tumors
China
China

Drugs Candidate:PD-L1

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
TMB-H Solid Tumors -China - Monotherapy
Monotherapy
Solid Tumors -China - Combo with VEGFRi
Combo with VEGFRi
Global
In-house
READ MORE READ MORE
Non-oncology
Drugs
Candidate
Target
Indication
Clinical Trial
Region
Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
Ph IIb/Ph III
Rights
Partner
TST002
Sclerostin
Osteoporosis
China

Drugs Candidate:Sclerostin

Right:Greater China

Partner:In-licensed from Eli Lilly

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
PH 2b/PH 3
Osteoporosis -China - Monotherapy
Monotherapy
Greater China
In-licensed from Eli Lilly
READ MORE READ MORE
TST004
MASP2
TMA/IgA Nephropathy
Global

Drugs Candidate:MASP2

Right:Global

Partner:Co-development with Alebund in Greater China

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
PH 2b/PH 3
TMA/IgA Nephropathy -Global - Monotherapy
Monotherapy
Global
Co-development with Alebund in Greater China
READ MORE READ MORE
TST008
MASP2-based Tri-functional (FIC)
SLE
Global

Drugs Candidate:MASP2-based Tri-functional (FIC)

Right:Global

Partner:In-house

Preclinical
IND
Ph Ia
Ph Ib /
Ph IIa
Pivotal
PH 2b/PH 3
SLE -Global - Monotherapy
Monotherapy
Global
In-house
READ MORE READ MORE
TOP
肿瘤

MSB2311*

靶点:PD-L1

适应症:TMB-H 实体瘤

临床实验地区:中国

权利:全球

合伙人:内部

MSB2311 是靶向结合 PD-L1 的研究性 pH 依赖性人源化抗体。

PD-L1 参与抑制了对抗癌症的免疫系统应答,在实体瘤患者的肿瘤细胞中PD-L1表达水平显著升高。MSB2311 使用了工程改造去除了和Fc受体结合的人源IgG1。MSB2311 可与肿瘤细胞上的 PD-L1 结合,并阻断 PD-L1 和 PD-1(T效应细胞上的受体)的相互作用。此外,MSB2311 与 PD-L1 的结合引发 MSB2311 的内吞,当进入 pH 值低于5.5 的核内体时,MSB2311 可从结合的 PD-L1 上分离, MSB2311 可在 FcRn 的帮助下再循环到质膜,并重新与其他肿瘤细胞上的 PD-L1 结合。临床前研究结果表明,MSB2311 在同源小鼠模型中可抑制有表达 PD-L1 的肿瘤细胞的肿瘤生长。